# Section 8B: The Broader EoE Competitive Pipeline

## Standard of Care Today

Eosinophilic esophagitis is currently managed with a small set of tools that either reduce acid exposure, suppress local inflammation, remove inciting antigens from the diet, or blunt a specific cytokine signal — none of which address the underlying antigen-driven immune response.

Proton pump inhibitors (PPIs) remain a first-line intervention, reflecting the substantial overlap between EoE and acid-mediated esophageal pathology and the fact that a meaningful subset of patients achieve histologic remission on PPI therapy alone, likely through effects on epithelial barrier function and cytokine signaling rather than acid suppression per se. Swallowed topical corticosteroids are a second pillar: budesonide oral suspension (marketed as EOHILIA) has received formal regulatory approval for EoE, and fluticasone delivered via inhaler-swallowed technique is widely used off-label. Both approaches suppress local eosinophilic and Th2-driven inflammation but require ongoing administration to maintain effect. Dietary elimination therapy — empiric or targeted removal of common trigger foods (milk, wheat, egg, soy, and others) — offers a non-pharmacologic route to remission by removing the antigenic trigger itself, but it is burdensome, requires sequential food reintroduction and repeat endoscopy/biopsy to identify triggers, and adherence is a persistent challenge.

The most significant recent addition to this landscape is dupilumab (Dupixent), an anti-IL-4Rα monoclonal antibody that blocks both IL-4 and IL-13 signaling. Its approval for EoE in 2022 marked the first biologic sanctioned for this indication and validated the Th2 axis as a druggable target in EoE. Dupilumab is administered as a chronic injectable therapy; like the other standard-of-care options, it manages disease activity rather than resolving the underlying antigen-specific immune drive.

## The Biologic Wave

Dupilumab's approval has catalyzed a broader wave of biologic development aimed at various nodes of the type 2 inflammatory cascade implicated in EoE pathogenesis. These programs share a common conceptual architecture: identify a cytokine or receptor upstream or downstream of the eosinophil/Th2 axis and block it systemically.

Anti-IL-5 and anti-IL-5 receptor agents (mepolizumab and benralizumab, respectively) target eosinophil survival and maturation directly; both have been investigated in eosinophilic gastrointestinal diseases, including EoE, given the centrality of eosinophils to tissue pathology, though their role and positioning relative to dupilumab in EoE specifically continues to evolve. Anti-IL-13 approaches, such as cendakimab, aim at the cytokine most directly implicated in esophageal epithelial remodeling and eotaxin-3 induction. Anti-TSLP strategies target further upstream, at the epithelial alarmin thought to initiate the type 2 cascade in response to allergen or irritant exposure — an approach with precedent in asthma that is being explored in eosinophilic esophageal disease. Anti-Siglec-8 therapy (lirentelimab) has been studied in EoE and related eosinophilic GI disorders as a mechanism to deplete or inhibit eosinophils and mast cells directly, with results across this program's trials described as mixed; its ultimate role in EoE, if any, remains unsettled. Sphingosine-1-phosphate (S1P) receptor modulators, which limit lymphocyte trafficking, represent a further mechanistic category under exploration, drawing on precedent from inflammatory bowel disease and other immune-mediated conditions. For several of these agents, EoE-specific development status, trial outcomes, and regulatory pathways remain in flux, and this section does not assert specific results or approval timelines beyond what is well established for dupilumab and the topical/PPI standard of care.

## What None of Them Do: The Tolerance Gap

Despite mechanistic diversity — spanning acid suppression, corticosteroid-mediated immune suppression, cytokine blockade at multiple nodes, and eosinophil/mast cell depletion — every therapy described above shares a defining structural feature: it is anti-inflammatory, not tolerogenic. Each works by continuously suppressing a downstream or upstream node of the immune response, and none is designed to retrain the adaptive immune system's antigen-specific recognition of the food or environmental triggers that drive disease.

The practical consequence is that all of these therapies require indefinite dosing to maintain effect. Discontinuation — whether of a PPI, a topical steroid, an elimination diet, or a biologic — is typically followed by histologic and symptomatic relapse, because the underlying antigen-specific T cell and IgG4/IgE responses that perpetuate esophageal eosinophilic inflammation remain intact and are simply being masked or dampened rather than corrected. Elimination diets come closest to addressing antigen exposure directly, but they act by avoidance rather than by inducing tolerance, and they carry no mechanism for enabling a patient to safely reintroduce a trigger food.

This is the whitespace: no approved or late-stage EoE therapy today is designed to induce durable, antigen-specific immune tolerance. The field has developed an increasingly sophisticated toolkit for suppressing the consequences of the immune response, but nothing that addresses its cause at the level of antigen-specific T cell education.

## Positioning a pMHC Vaccine

An antigen-specific pMHC-based vaccine approach occupies a category distinct from every therapy described above: it is positioned as disease-modifying rather than chronic-suppressive. Rather than continuously blocking a cytokine or depleting an effector cell population, the intent is to re-educate the antigen-specific T cell response directly, with the goal of durable remission that persists after dosing is reduced or stopped — the inverse of the relapse-on-discontinuation pattern that characterizes the current standard of care and the biologic pipeline alike.

This positioning also suggests combination and sequencing opportunities rather than pure substitution. A pMHC vaccine could plausibly be introduced after biologic- or steroid-induced remission, using anti-inflammatory therapy to quiet active eosinophilic disease while the tolerizing intervention re-shapes the underlying antigen-specific response, with anti-inflammatory agents subsequently tapered as tolerance is established. This complementary framing — chronic-suppressive therapy for induction, antigen-specific therapy for durable maintenance — differentiates the mechanism from a head-to-head competitive threat to dupilumab or the emerging biologics, and instead frames it as addressing the one gap none of them were designed to close.